Home / Peptide legality / New Mexico
Are peptides legal in New Mexico?
Peptides occupy a gray legal zone in New Mexico: FDA-approved peptide medicines are legal under a valid prescription, while unapproved research peptides such as BPC-157 and TB-500 remain outside the lawful medical supply chain.
Legal status overview
Peptides occupy a gray legal zone in New Mexico, where legality hinges on the individual peptide and how it is obtained. FDA-approved peptide drugs, including brand GLP-1 medicines like Wegovy® (semaglutide) and Mounjaro® (tirzepatide), are legal to prescribe and dispense through New Mexico licensed pharmacies. New Mexico regulates pharmacy practice under its Pharmacy Act and Board of Pharmacy rules and has no standalone peptide ban, so state legality tracks the federal 503A and 503B compounding framework. Research peptides such as BPC-157 and TB-500 are not FDA-approved, are no longer clearly eligible for compounding, and are usually sold only as research chemicals, which places them outside lawful clinical use.
Key points
- New Mexico has no statute that specifically bans peptides; state legality follows the federal 503A and 503B compounding framework combined with New Mexico Board of Pharmacy licensing and prescription rules. [1]
- New Mexico regulates pharmacy practice and drug distribution through its Pharmacy Act within the New Mexico Statutes Annotated 1978, administered by the Board of Pharmacy. [6]
- State pharmacy boards can add requirements above the federal floor, so peptide access in New Mexico depends on both federal eligibility and Board of Pharmacy enforcement. [7]
- A peptide qualifies for 503A compounding only if it is on the FDA 503A Bulks List (Category 1), has a USP or NF monograph, or is a component of an FDA-approved drug. [1]
- Compounded GLP-1 medicines are no longer routinely available after the FDA declared the tirzepatide and semaglutide shortages resolved in 2025 and set deadlines to stop mass compounding. [2]
- BPC-157 and TB-500 were removed from FDA Category 2 in 2026 but not added to the Category 1 Bulks List, leaving them in regulatory limbo rather than cleared for compounding. [4]
- The FDA Pharmacy Compounding Advisory Committee reviewed BPC-157 and TB-500 in July 2026, confirming the status of these peptides is still unresolved. [3]
- Growth hormone (somatropin) is legal only by prescription for FDA-recognized conditions; federal law makes distribution for anti-aging or athletic use a crime even with a prescription. [5]
Compound-by-compound status
| BPC-157 Gray area | Not FDA-approved; not a generic; not evaluated by the FDA. Removed from FDA Category 2 in 2026 but not placed on the Category 1 Bulks List, so it is not clearly eligible for routine 503A compounding in New Mexico and is mostly sold as a research chemical. |
|---|---|
| GLP-1 class (semaglutide, tirzepatide) Restricted | FDA-approved brand products such as Wegovy® (semaglutide), Ozempic® (semaglutide), Zepbound® (tirzepatide), and Mounjaro® (tirzepatide) are legal by prescription. Compounded versions are not FDA-approved; not a generic; not evaluated by the FDA, and are limited to narrow documented-need cases now that the shortages are resolved. |
| TB-500 (thymosin beta-4 fragment) Gray area | Not FDA-approved; not a generic; not evaluated by the FDA. Under FDA advisory-committee review for the 503A Bulks List and typically sold only as a research chemical, so lawful clinical access in New Mexico is limited. |
| Growth hormone / somatropin Restricted | A prescription drug legal only for FDA-recognized medical conditions. Federal law (21 USC 333(e)) makes distribution for anti-aging, bodybuilding, or athletic enhancement a crime even with a prescription. |
Frequently asked questions
Are peptides legal in New Mexico?
It depends on the peptide. FDA-approved peptide medicines are legal with a valid prescription from a New Mexico licensed provider. Unapproved research peptides such as BPC-157 and TB-500 are not clearly available through lawful compounding, so they sit in a gray zone. This is general information, not legal or medical advice.
Can I still get compounded GLP-1 medicines in New Mexico?
Only in limited cases. After the FDA resolved the semaglutide and tirzepatide shortages in 2025, routine compounding wound down. Compounded versions are not FDA-approved; not a generic; not evaluated by the FDA. Most patients are moved to FDA-approved brands such as Wegovy® (semaglutide) or Mounjaro® (tirzepatide).
Do I need a prescription for peptides in New Mexico?
Yes. A peptide dispensed for human use must be tied to a valid, patient-specific prescription from a provider licensed in New Mexico. Products labeled as research chemicals are not authorized for human use.
Is BPC-157 legal in New Mexico?
BPC-157 is not FDA-approved and remains in federal compounding limbo after being removed from Category 2 without being added to the approved Bulks List. New Mexico has no separate ban, but the federal status limits lawful medical access.
Who regulates peptide compounding in New Mexico?
The New Mexico Board of Pharmacy oversees pharmacy licensing and compounding within the state, working alongside the federal FDA framework that determines which peptides may be compounded.
Sources
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (FDA) (retrieved 2026-09-21)
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (FDA) (retrieved 2026-09-21)
- July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (FDA) (retrieved 2026-09-21)
- BPC-157 in 2026: Why Regulatory Limbo Is Not the Same as a Green Light (Holt Law) (retrieved 2026-09-21)
- 21 U.S. Code 333(e) definition of human growth hormone (Cornell Legal Information Institute) (retrieved 2026-09-21)
- Senate Bill 353, amending certain sections of the NMSA 1978 (New Mexico Legislature) (retrieved 2026-09-21)
- Peptide Compounding Regulations: Why State Laws Vary (RethinkPeptides) (retrieved 2026-09-21)
Last researched: 2026-09-21.